Download PDF
Dtsch Med Wochenschr 2015; 140(08): 612-615
DOI: 10.1055/s-0041-100777
Fachwissen
Aus Fachgremien
© Georg Thieme Verlag KG Stuttgart · New York

Cytomegalievirus bei Nierentransplantation – Diagnose, Prävention und Management

Cytomegalovirus after renal transplantation – diagnosis, prevention and treatment
Volker Kliem
1   Abteilung Innere Medizin/Nephrologie, Nephrologisches Zentrum Niedersachsen, Hann. Münden
,
Martina Sester
2   Abteilung für Transplantations- und Infektionsimmunologie, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg/Saar
,
Martin Nitschke
3   Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
,
Burkhard Tönshoff
4   Zentrum für Kinder- und Jugendmedizin, Klinik Kinderheilkunde I, Universitätsklinikum Heidelberg
,
Klemens Budde
5   Medizinische Klinik mit Schwerpunkt Nephrologie, Charité - Universitätsmedizin Berlin
,
Ingeborg A. Hauser
6   Funktionsbereich Nephrologie, Medizinische Klinik III, Universitätsklinikum Frankfurt, Goethe-Universität
,
Michael Schmitt
7   Medizinische Klinik V, Universitätsklinikum Heidelberg
,
Britta Höcker
4   Zentrum für Kinder- und Jugendmedizin, Klinik Kinderheilkunde I, Universitätsklinikum Heidelberg
,
Oliver Witzke
8   Klinik für Nephrologie, Universitätsklinikum Essen, Universität Duisburg-Essen
› Author Affiliations
Further Information

Publication History

Publication Date:
16 April 2015 (online)

Also available at
    Permissions and Reprints

Das Cytomegalievirus (CMV) ist die häufigste virale Infektion, die nach der Transplantation solider Organe zu schwerwiegenden Komplikationen führen kann. Eine deutsche Expertengruppe hat nun die im Jahr 2013 veröffentlichten internationalen Konsensus-Leitlinien zu CMV bei Transplantation solider Organe zusammengefasst und bewertet.

Schlüsselwörter

CMV-Diagnose - CMV-Prävention - CMV-Therapie

Key Words

diagnosis of CMV - prevention of CMV - treatment of CMV

Supporting Information

 

  • Literaturverzeichnis

  • 1 Asberg A, Humar A, Jardine AG et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205-1213
    CrossrefPubMedGoogle Scholar
  • 2 Boivin G, Goyette N, Farhan M et al. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 2012; 53: 208-213
    CrossrefPubMedGoogle Scholar
  • 3 Brennan DC, Legendre C, Patel D et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453-2462
    CrossrefPubMedGoogle Scholar
  • 4 Cervera C, Fernandez-Ruiz M, Valledor A et al. Epidemiology and risk factors for late infection in solid organ transplant recipients. Transpl Infect Dis 2011; 13: 598-607
    CrossrefPubMedGoogle Scholar
  • 5 Dickenmann MJ, Cathomas G, Steiger J et al. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001; 71: 764-767
    CrossrefPubMedGoogle Scholar
  • 6 Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010; 10: 157-161
    CrossrefPubMedGoogle Scholar
  • 7 Ekberg H, Bernasconi C, Noldeke J et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004-2010
    CrossrefPubMedGoogle Scholar
  • 8 Fachinformation. Valcyte® 50 mg / ml Pulver zur Herstellung einer Lösung zum Einnehmen (Mono). Stand: April 2013. FachInfo-Service; 2013
    PubMedGoogle Scholar
  • 9 Fortun J, Martin-Davila P, Pascual J et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12: 397-405
    CrossrefPubMedGoogle Scholar
  • 10 Gracia-Ahufinger I, Gutierrez-Aroca J, Cordero E et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation 2013; 95: 1015-1020
    CrossrefPubMedGoogle Scholar
  • 11 Halme L, Lempinen M, Arola J et al. High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients. APMIS 2008; 116: 99-106
    CrossrefPubMedGoogle Scholar
  • 12 Hodson EM, Ladhani M, Webster AC et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2 CD003774
    PubMedGoogle Scholar
  • 13 Humar A, Limaye AP, Blumberg EA et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427-1431
    CrossrefPubMedGoogle Scholar
  • 14 Kliem V, Fricke L, Wollbrink T et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983
    CrossrefPubMedGoogle Scholar
  • 15 Kotton CN, Kumar D, Caliendo AM et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360
    CrossrefPubMedGoogle Scholar
  • 16 Kranz B, Vester U, Wingen AM et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008; 12: 474-478
    CrossrefPubMedGoogle Scholar
  • 17 Lautenschlager I, Halme L, Hockerstedt K et al. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006; 8: 21-30
    CrossrefPubMedGoogle Scholar
  • 18 Le Page AK, Jager MM, Iwasenko JM et al. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013; 56: 1018-1029
    CrossrefPubMedGoogle Scholar
  • 19 Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097
    CrossrefPubMedGoogle Scholar
  • 20 McLaughlin K, Wu C, Fick G et al. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation 2002; 74: 813-816
    CrossrefPubMedGoogle Scholar
  • 21 Owers DS, Webster AC, Strippoli GF et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2 CD005133
    PubMedGoogle Scholar
  • 22 Ozaki KS, Camara NO, Nogueira E et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transplant 2007; 21: 675-680
    CrossrefPubMedGoogle Scholar
  • 23 Pescovitz MD. Prevention and treatment of cytomegalovirus disease in solid organ transplant recipients: the clinical and economic impact of evolving strategies. Introduction. Am J Health Syst Pharm 2003; 60 (Suppl. 08) S3-S4
    PubMedGoogle Scholar
  • 24 Pilmore H, Pussell B, Goodman D. KHA-CARI guideline: cytomegalovirus disease and kidney transplantation. Nephrology 2011; 16: 683-687
    CrossrefPubMedGoogle Scholar
  • 25 Ritter M, Schmidt T, Dirks J et al. Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol 2013; 43: 1099-1108
    CrossrefPubMedGoogle Scholar
  • 26 Robert Koch-Institut. Epidemiologisches Bulletin. Nr. 3, Januar 2014
    Google Scholar
  • 27 Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Intern 2004; 66: 329-337
    CrossrefPubMedGoogle Scholar
  • 28 Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174
    CrossrefPubMedGoogle Scholar
  • 29 San Juan R, Aguado JM, Lumbreras C et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47: 875-882
    CrossrefPubMedGoogle Scholar
  • 30 Sester M, Gärtner BC, Sester U. Monitoring of CMV-specific T-cell levels after organ transplantation. J Lab Med 2008; 32: 121-130
    PubMedGoogle Scholar
  • 31 Smith JM, Corey L, Bittner R et al. Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol 2010; 21: 1579-1586
    CrossrefPubMedGoogle Scholar
  • 32 Stitt N. Infection in the Transplant Recipient. Medscape Online; 2003. http://www.medscape.com/viewarticle/451788 Letzter Zugriff: 18. 02. 2015
    Google Scholar
  • 33 Tong CY, Bakran A, Peiris JS et al. The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation. Transplantation 2002; 74: 576-578
    CrossrefPubMedGoogle Scholar
  • 34 van Son WJ, de Maar EF, van Der Bij W et al. Overcoming the problem of cytomegalovirus infection after organ transplantation: calling for Heracles?. Intervirology 1999; 42: 285-290
    CrossrefPubMedGoogle Scholar
  • 35 Westall GP, Michaelides A, Williams TJ et al. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004; 190: 1076-1083
    CrossrefPubMedGoogle Scholar
  • 36 Witzke O, Hauser IA, Bartels M et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012; 93: 61-68
    CrossrefPubMedGoogle Scholar